Functional Outcomes After Localized Prostate Cancer Treatment
JAMA · 23.01.2024 · 331 (4) · 302
DOI: 10.1001/jama.2023.26491 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 23.01.2024. Verfasst von Bashir Al Hussein Al Awamlh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AHRQ HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Importance Adverse outcomes associated with treatments for localized prostate cancer remain unclear.
Objective
To compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. Design, Setting, and Participants An observational cohort study using data from 5 US Surveillance, Epidemiology, and End Results Program registries. Participants were treated for localized prostate cancer between 2011 and 2012. At baseline, 1877 had favorable-prognosis prostate cancer (defined as cT1-cT2bN0M0, prostate-specific antigen level <20 ng/mL, and grade group 1-2) and 568 had unfavorable-prognosis prostate cancer (defined as cT2cN0M0, prostate-specific antigen level of 20-50 ng/mL, or grade group 3-5). Follow-up data were collected by questionnaire through February 1, 2022. Exposures Radical prostatectomy (n = 1043), external beam radiotherapy (n = 359), brachytherapy (n = 96), or active surveillance (n = 379) for favorable-prognosis disease and radical prostatectomy (n = 362) or external beam radiotherapy with androgen deprivation therapy (n = 206) for unfavorable-prognosis disease. Main Outcomes and Measures Outcomes were patient-reported sexual, urinary, bowel, and hormone function measured using the 26-item Expanded Prostate Cancer Index Composite (range, 0-100; 100 = best). Associations of specific therapies with each outcome were estimated and compared at 10 years after treatment, adjusting for corresponding baseline scores, and patient and tumor characteristics. Minimum clinically important differences were 10 to 12 for sexual function, 6 to 9 for urinary incontinence, 5 to 7 for urinary irritation, and 4 to 6 for bowel and hormone function.
Results
A total of 2445 patients with localized prostate cancer (median age, 64 years; 14% Black, 8% Hispanic) were included and followed up for a median of 9.5 years. Among 1877 patients with favorable prognosis, radical prostatectomy was associated with worse urinary incontinence (adjusted mean difference, −12.1 [95% CI, −16.2 to −8.0]), but not worse sexual function (adjusted mean difference, −7.2 [95% CI, −12.3 to −2.0]), compared with active surveillance. Among 568 patients with unfavorable prognosis, radical prostatectomy was associated with worse urinary incontinence (adjusted mean difference, −26.6 [95% CI, −35.0 to −18.2]), but not worse sexual function (adjusted mean difference, −1.4 [95% CI, −11.1 to 8.3), compared with external beam radiotherapy with androgen deprivation therapy. Among patients with unfavorable prognosis, external beam radiotherapy with androgen deprivation therapy was associated with worse bowel (adjusted mean difference, −4.9 [95% CI, −9.2 to −0.7]) and hormone (adjusted mean difference, −4.9 [95% CI, −9.5 to −0.3]) function compared with radical prostatectomy. Conclusions and Relevance Among patients treated for localized prostate cancer, radical prostatectomy was associated with worse urinary incontinence but not worse sexual function at 10-year follow-up compared with radiotherapy or surveillance among people with more favorable prognosis and compared with radiotherapy for those with unfavorable prognosis. Among men with unfavorable-prognosis disease, external beam radiotherapy with androgen deprivation therapy was associated with worse bowel and hormone function at 10-year follow-up compared with radical prostatectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
- Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Center, Nashville.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
- Office of Patient and Community Education, Patient Advocacy Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Förderung
- NCI NIH HHS
- AHRQ HHS
- NCATS NIH HHS
Zitieren
APA
Al Hussein Al Awamlh, B., Wallis, C. J. D., Penson, D. F., Huang, L. C., Zhao, Z., Conwill, R., Talwar, R., Morgans, A. K., Goodman, M., Hamilton, A. S., Wu, X. C., Paddock, L. E., Stroup, A., O'Neil, B. B., Koyama, T., Hoffman, K. E., & Barocas, D. A. (2024). Functional Outcomes After Localized Prostate Cancer Treatment. JAMA, 331(4), 302. https://doi.org/10.1001/jama.2023.26491
Vancouver
Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, et al. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024;331(4):302. doi:10.1001/jama.2023.26491
BibTeX
@article{AlHusseinAlAwamlh2024,
author = {Al Hussein Al Awamlh, Bashir and Wallis, Christopher J D and Penson, David F and Huang, Li-Ching and Zhao, Zhiguo and Conwill, Ralph and Talwar, Ruchika and Morgans, Alicia K and Goodman, Michael and Hamilton, Ann S and Wu, Xiao-Cheng and Paddock, Lisa E and Stroup, Antoinette and O'Neil, Brock B and Koyama, Tatsuki and Hoffman, Karen E and Barocas, Daniel A},
title = {Functional Outcomes After Localized Prostate Cancer Treatment},
journal = {JAMA},
year = {2024},
volume = {331},
number = {4},
pages = {302},
doi = {10.1001/jama.2023.26491}
}
EUVIMED